Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Concomitant FSHD1 and FSHD2 in a Pediatric Patient with an Early Onset Severe Phenotype
Neuromuscular and Clinical Neurophysiology (EMG)
P3 - Poster Session 3 (5:30 PM-6:30 PM)
11-009

Facioscapulohumeral dystrophy (FSHD) is an autosomal dominant form of muscular dystrophy characterized by progressive asymmetric muscle weakness involving the face, shoulder girdle, abdomen, and legs. FSHD arises in the context of toxic DUX4 protein expression, which typically occurs when the D4Z4 tandem repeats, each carrying a copy of the DUX4 gene, becomes permissively contracted (1-10 repeats; FSHD1). In approximately 5% of patients, DUX4 expression results from hypomethylation of the D4Z4 repeats (FSHD2). Here, we present a pediatric patient with an early onset, severe phenotype of FSHD with genetically confirmed FSHD1 and FSHD2. 

NA
NA

The patient is a 12-year-old girl who came to medical attention at 2 years of age due to lumbar lordosis. She was conceived via in vitro fertilization using a donor egg with pregnancy complicated by pre-eclampsia. Neonatal course was unremarkable. She met normal developmental milestones and walked at 15 months, but was slower than peers, requiring frequent breaks. She had difficulty climbing stairs and rising from the ground. Exam at age 12 was notable for pectus excavatum, significant lumbar lordosis, straight clavicles, scapular winging, and hip flexion contractures. Neurologic exam demonstrated bifacial weakness, significant neck flexion weakness, proximal greater than distal weakness with shoulder and pelvic girdle muscles rated 2/5, and positive Beevor sign. She ambulated short distances with a walker. Initially, genetic testing revealed D4Z4 hypomethylation (10%) and one FSHD-permissive 4qA allele without repeat contraction or SMCHD1 mutation. Repeat genetic testing revealed a D4Z4 duplication on the 4qA allele with one copy having 54 repeat units and the second having 2 repeat units. A pathogenic mutation in SMCHD1 was uncovered. These results confirmed a diagnosis of both FSHD1 and FSHD2. 

Concomitant FSHD1 and FSHD2 is an extremely rare occurrence with individuals presenting with a severe phenotype suggesting a synergistically deleterious effect of these genetic changes. 

Authors/Disclosures
Brianna Brun (Strong Memorial Hospital)
PRESENTER
Dr. Brun has nothing to disclose.
Alrabi Tawil, MD, FAAN (University of Rochester Medical Center) Dr. Tawil has received personal compensation in the range of $500-$4,999 for serving as a Consultant for DYNE Therapeutics. Dr. Tawil has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arrowhead Pharma. Dr. Tawil has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Fulcrum Therapeutics. Dr. Tawil has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acceleron Pharma. Dr. Tawil has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MT Pharma. Dr. Tawil has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Pharma. Dr. Tawil has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for miRecule. The institution of Dr. Tawil has received research support from Friends of FSH Research. The institution of Dr. Tawil has received research support from FSH Society. The institution of Dr. Tawil has received research support from NIH. The institution of Dr. Tawil has received research support from Fulcrum. Dr. Tawil has received intellectual property interests from a discovery or technology relating to health care. Dr. Tawil has received publishing royalties from a publication relating to health care.
Samuel Mackenzie, MD, PhD (Nationwide Children's Hospital) Dr. Mackenzie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Phlow, Corp. Dr. Mackenzie has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Everyday Health, Inc. Dr. Mackenzie has received intellectual property interests from a discovery or technology relating to health care.